National Taiwan University

Academia Sinica

Wei-Yun Lai

Pan-Chyr Yang

Konan Peck

Yi-Chung Chang

Chi-Yuan Chen

Bo-Tsang Huang

Shuenn-Chen Yang

Cheng-Ju Chang

Jen-Wei Wang

Nucleic acid aptamers that bind to tumor necrosis factor alpha (TNF). Also provided herein are pharmaceutical compositions comprising such anti-TNF aptamers and methods for the using the same for therapeutic and diagnostic applications, for example, alleviating liver injury and monitoring presence of TNF in vivo or in vitro.

TNF-targeting aptamers and uses thereof for treatment or diagnosing TNF-related inflammatory diseases

Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.

Antagonistic PDL1 aptamers and their applications in cancer therapy

Aptamers that bind to and antagonize programmed cell death protein 1 (PD-1). Also provided herein are pharmaceutical compositions comprising such anti-PD-1 aptamers and methods for using the same for promoting T cell proliferation, treating cancer or infectious diseases, such as human immunodeficiency virus (HIV) infection.

Antagonistic PD-1 aptamer and its applications in cancer therapy related applications

The invention provides DNAzymes which are capable to silence the expression of EGFR at allele-specific level. These allele-specific DNAzymes against EGFR T790M mutation will knockdown the expression of EGFR T790M mRNA while keeping EGFR wild-type mRNA intact. Hence, these allele-specific DNAzymes against EGFR T790M mutation may overcome T790M-derived TKI resistance accompanied with lower unwanted side effects on normal cells in lung cancer patients.

Growing community of inventors

Taipei, Taiwan

Wei-Yun Lai